Search - tctmd.com

Displaying 21 - 40 of 42

Sort: Relevancy | Date

News Conference News EuroPCR 2016

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Yael L. Maxwell

May 17, 2016

News Daily News

Sluggish CMS Reimbursement Lags Cardiac Device Approvals: Should Value Endpoints be Added to Trials?

Yael L. Maxwell

May 02, 2016

News Daily News

Los Lentos Reembolsos de los CMS Lastran las Aprobaciones de Dispositivos Cardíacos: ¿Deberían de Incorporarse a los Ensayos Puntos Finales sobre el Valor?

Yael L. Maxwell

May 02, 2016

News Daily News

CMS 报销滞后拖慢了心脏装置批准过程：瓣膜终点是否应加入试验当中？

Yael L. Maxwell

May 02, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for April 2016

Shelley Wood

April 29, 2016

News Conference News ACC 2016

New-Generation Watchman FLX Device Pulled From European Shelves Over Embolism Concerns

Todd Neale

April 04, 2016

News Conference News ACC 2016

Watchman Left Atrial Appendage Closure Device Fares Well in Early Commercial Experience

Todd Neale

April 03, 2016

News Daily News

Final CMS Decision Memo for Watchman Dumps Controversial Warfarin Contraindication

Shelley Wood

February 08, 2016

News Daily News

La FDA Da la Voz de Alarma sobre el Uso del Dispositivo Lariat para el Cierre del AAI en Pacientes con FA

Yael L. Maxwell

July 17, 2015

News Daily News

FDA对在房颤患者中使用Lariat左心耳封堵装置发出警示

Yael L. Maxwell

July 17, 2015

News Daily News

FDA Sounds Alarm Bells Over Use of Lariat Device for LAA Closure in A-fib Patients

Yael L. Maxwell

July 17, 2015

News Daily News

Un Meta Análisis Revela que Watchman sigue Sin ser Inferior a Warfarina y Da Buenos Resultados de Seguridad

Yael L. Maxwell

June 17, 2015

News Daily News

Meta-analysis Shows Watchman Still Noninferior to Warfarin, With Good Safety Outcomes

Yael L. Maxwell

June 17, 2015

News Daily News

Meta 分析表明 Watchman 依旧不逊于华法林，患者结局良好及安全

Yael L. Maxwell

June 17, 2015

News Industry News

University of Michigan Health System among first in nation to use new device for stroke prevention

May 15, 2015

News Daily News

Oclusión de LAA más rentable que la warfarina y que el dabigatran para pacientes con fibrilación auricular

Yael L. Maxwell

June 07, 2013

News Daily News

LAA Occlusion More Cost-effective Than Both Warfarin and Dabigatran for A-fib Patients

Yael L. Maxwell

June 07, 2013

News Daily News

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

Caitlin E. Cox

January 30, 2013

News Daily News

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Caitlin E. Cox

January 30, 2013

News Daily News

Watchman Works Just as Well Without Warfarin-Protected Transition

June 01, 2012

Advertisement

EWOLUTION Confirms Safety, Efficacy for Real-World Use of Watchman, Even With No Postprocedural Drug Therapy

Sluggish CMS Reimbursement Lags Cardiac Device Approvals: Should Value Endpoints be Added to Trials?

Los Lentos Reembolsos de los CMS Lastran las Aprobaciones de Dispositivos Cardíacos: ¿Deberían de Incorporarse a los Ensayos Puntos Finales sobre el Valor?

CMS 报销滞后拖慢了心脏装置批准过程：瓣膜终点是否应加入试验当中？

TCTMD’s Top 10 Most Popular Stories for April 2016

New-Generation Watchman FLX Device Pulled From European Shelves Over Embolism Concerns

Watchman Left Atrial Appendage Closure Device Fares Well in Early Commercial Experience

Final CMS Decision Memo for Watchman Dumps Controversial Warfarin Contraindication

La FDA Da la Voz de Alarma sobre el Uso del Dispositivo Lariat para el Cierre del AAI en Pacientes con FA

FDA对在房颤患者中使用Lariat左心耳封堵装置发出警示

FDA Sounds Alarm Bells Over Use of Lariat Device for LAA Closure in A-fib Patients

Un Meta Análisis Revela que Watchman sigue Sin ser Inferior a Warfarina y Da Buenos Resultados de Seguridad

Meta-analysis Shows Watchman Still Noninferior to Warfarin, With Good Safety Outcomes

Meta 分析表明 Watchman 依旧不逊于华法林，患者结局良好及安全

University of Michigan Health System among first in nation to use new device for stroke prevention

Oclusión de LAA más rentable que la warfarina y que el dabigatran para pacientes con fibrilación auricular

LAA Occlusion More Cost-effective Than Both Warfarin and Dabigatran for A-fib Patients

PROTECT AF: Longer Follow-up Provides Clarity on Watchman vs. Warfarin for A-fib

PROTECT AF: El Seguimiento a Más Largo Plazo Aclara la Situación del Dispositivo Watchman frente a la Warfarina contra la FA

Watchman Works Just as Well Without Warfarin-Protected Transition

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content